![](/img/cover-not-exists.png)
Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine
Mar Garcia, Jorge E. Romaguera, Kedar V. Inamdar, George Z. Rassidakis, L. Jeffrey MedeirosVolume:
115
Year:
2009
Language:
english
Pages:
8
DOI:
10.1002/cncr.24141
File:
PDF, 393 KB
english, 2009